Safety of hormone therapy after breast cancer: A qualitative systematic review

Human Reproduction

Volumn 22, Issue 2, 2007, Pages 616-622

  Antoine, C ^a   Liebens, F ^a   Carly, B ^a   Pastijn, A ^a   Neusy, S ^a   Rozenberg, Serge ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Breast cancer; Hormone therapy; Mortality; Recurrence rates; Treatments

Indexed keywords

CLONIDINE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HORMONE; SOTALOL; TAMOXIFEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG SAFETY; FOLLOW UP; HUMAN; META ANALYSIS; METHODOLOGY; POPULATION RESEARCH; PROGNOSIS; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; RANDOMIZATION; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW;

EID: 33846480129     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del393     Document Type: Review

References (57)

1. American Cancer Society (ACS) (2004) Cancer Statistics-Presentation.
2. Batur P, Blixen CE, Moore HCF and Thacker HL and Xu M (2006) Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas 53(2),123-132.
3. Beckmann MW, Jap D, Djahansouzi S, Nestle-Kramling C, Kuschel B, Dall P, Brumm C and Bender HG (2001) Hormone replacement therapy after treatment of breast cancer: Effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 60(3),199-206.
4. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JDF and Feuer EJ; The Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353,1784-1792.
5. Bluming AZ, Waisman JR, Dosik GM, Olsen GA, McAndrew P, Decker RW, Rosenbloom BE, Terpenning M, Klein JH, Van Sco MM et al. (1998) Hormone replacement therapy (HRT) in women with previously treated primary breast cancer. Update IV (Meeting abstract) ASCO Annual Meeting. [Abstract No. 496].
6. Bluming VA, Waisman JR, Dosik GM, Olsen GA, Rosenbloom BE, McAndrew P, Terpenning M, Decker RW, Klein JH, Van Sco MM et al. (1999) Hormone Replacement Therapy (HRT) in women with previously treated primary breast cancer. Update (Meeting abstract) ASCO Annual Meeting. [Abstract No. 471].
7. Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL and Creasman WT (1999) An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med 44(4),186-192.
8. Brzezinski A (1995) Management of menopause in women with breast cancer. Isr J Med Sci 31(2-3),163-168.
9. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA (2003) WHI and Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 289(24),3243-3253.
10. Cobleigh MA Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC and Wood WC (1994) Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA 272,540-545.
11. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB and Lau J (2001) Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk. J Clin Oncol 19(8),2357-2363.
12. Col NF, Kim JA and Chlebowski RT. Menopausal hormone therapy after breast cancer: A meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7(4): R535-R540. [Epub 19 May 2005].
13. Collins JA, Blake JM and Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11(6),545-560.
14. Decker DA, Pettinga JE, Cox TC, Burdakin JH, Jaiyesimi IA and Benitez PR (1997) Hormone replacement therapy in breast cancer survivors. Breast J 3(2),63-68.
15. Decker D, Pettinga J, Kestin L, Balasubramaniam M, Viccini F, Jaiyesimi I, Burdakin J, Benitez P and Ruark D (2000) Estrogen Replacement Therapy (ERT) in Breast Cancer Survivors ASCO Annual Meeting. [Abstract No. 2355].
16. Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L and Burdakin JH (2003) Estrogen replacement therapy in breast cancer survivors: A matched-controlled series. Menopause 10(4),277-285.
17. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P and Wren B (1998) A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1(2),137-142.
18. Dew JE, Wren BG and Eden JA (2003) A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6(1),45-52.
19. DiSaia PJ, Brewster WR, Ziogas A and Anton-Culver H (2000) Breast cancer survival and hormone replacement therapy: A cohort analysis. Am J Clin Oncol 23(6),541-545.
20. DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B and Anton-Culver H (1996) Hormone replacement therapy in breast cancer survivors: A cohort study. Am J Obstet Gynecol 174(5),1494-1498.
21. DiSaia PJ, Grosen EA, Odicino F, Cowan B, Pecorelli S, Wile AG and Creasman WT (1995) Replacement therapy for breast cancer survivors. A pilot study. Cancer 76(Suppl 10),2075-2078.
22. DiSaia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S and Wile AG (1993) Hormone replacement therapy in breast cancer. Lancet 342(8881),1232.
23. Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P and Eden JA (2002) Hormone replacement therapy after a diagnosis of breast cancer: Cancer recurrence and mortality. Med J Aust 177(7),347-351.
24. Eden JA, Bush T, Nand S and Wren BG (1995) A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 2(2),67-72.
25. Espie M, Gorins A, Perret F, Tournant B, Lipszyg J, Nowak H, Bedairia N and Marty M (1999) Hormone Replacement Therapy (HRT) in Patients (pts.) Treated for Breast Cancer: Analysis of a Cohort of 120 Patients (Meeting abstract) ASCO Annual Meeting. [Abstract No. 2262].
26. Ferlay J, Bray F, Pisani P and Parkin DM (2001) GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC Cancer-Base no. 5. Lyon, IARCPress.
27. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M and Hood N (1999) Risk of menopause during the first year after breast cancer diagnosis. Clin Oncol 17(8),2365-2370.
28. Gorins A, Espie M, Bedairia N, Perret F, Nowak H, Tournant B and Marty M (1998) Hormonal replacement therapy in menopause after breast cancer: first french study. Contracept Fertil Sex 26(10),696-699.
29. Gorins A, Espie M, Bedairia N, Perret F, Tournant B, Novak H, Lucchi-Angelier E and Marty M (2003) Hormone replacement therapy in breast cancer patients: A study of 230 patients, with a case-control study. Gynecol Obstet Fertil 31(7-8),614-619.
30. Guidozzi F (1999) Estrogen replacement therapy in breast cancer survivors. Int J Gynaecol Obstet 64(1),59-63.
31. Harris PF, Remington PL, Trentham-Dietz A, Allen CI and Newcomb PA (2002) Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 23(6),501-509.
32. Hickey M, Saunders CM and Stuckey BG (2005) Management of menopausal symptoms in patients with breast cancer: An evidence-based approach. Lancet Oncol 6(9),687-695.
33. Holli K, Isola J and Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. Clin Oncol 16(9),3115-3120.
34. Holmberg L and Anderson H; HABITS steering and data monitoring committees (2004) HABITS (hormonal replacement therapy after breast cancer - Is it safe?), a randomised comparison: Trial stopped. Lancet 363(9407),453-455.
35. Lower EE, Blau R, Gazder P and Tummala R (1999) The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 8(7),949-954.
36. Marchant DJ (1993) Estrogen-replacement therapy after breast cancer. Risks versus benefits. Cancer 71(Suppl 6),2169-2176.
37. Marsden J, Whitehead M, A'Hern R, Baum M and Sacks N (2000) Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 73(2),292-299.
38. Marttunen MB, Hietanen P, Pyrhonen S, Tiitinen A and Ylikorkala O (2001) A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy. Maturitas 39(3),217-225.
39. Meurer LN and Lena S (2002) Cancer recurrence and mortality in women using hormone replacement therapy: Meta-analysis. J Fam Pract 51(12),1056-1062.
40. Natrajan PK and Gambrell RD Jr (2002) Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 187(2),289-294; discussion 294-295.
41. Natrajan PK, Soumakis K and Gambrell RD Jr (1999) Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 181(2),288-295.
42. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE and Weiss NS (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93(10),754-762.
43. Peters GN, Fodera T, Sabol J, Jones S and Euhus D (2001) Estrogen replacement therapy after breast cancer: A 12-year follow-up. Ann Surg Oncol 8(10),828-832.
44. Peters GN and Jones SE (1996) Estrogen replacement therapy in breast cancer patients: A time for change? (Meeting abstract) ASCO Annual Meeting. [Abstract No. 148].
45. Powles TJ, Hickish T, Casey S and O'Brien M (1993) Hormone replacement after breast cancer. Lancet 342(8862),60-61.
46. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. (2002) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3),321-333.
47. von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. J Natl Cancer Inst. 97(7):533-5.
48. Spong CY and Scott JR (2004) Introducing the 'Level of Evidence' to Obstetrics & Gynecology. Obstet Gynecol 103,1-2.
49. Stoll BA (1989) Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 25(12),1909-1913.
50. Ursic-Vrscaj M and Bebar S (1999) A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 25(2),146-151.
51. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE and Theriault RL (1999) Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively. J Clin Oncol 17(5),1482-1487.
52. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL and Theriault RL (2002) Estrogen replacement therapy for menopausal women with a history of breast carcinoma: Results of a 5-year, prospective study. Cancer 95(9),1817-1826.
53. Vassilopoulou-Sellin R and Theriault RL (1994) Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J Natl Cancer Inst Monogr 16,153-159.
54. Vassilopoulou-Sellin R, Theriault R and Klein MJ (1997) Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 65(1),89-93.
55. Wile AG, Opfell RW and Margileth DA (1993) Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 165(3),372-375.
56. Wile AG, Opfell RW, Margileth DA and Anton-Culver H (1991) Hormone replacement therapy does not effect breast cancer outcome ASCO Annual Meeting. [Abstract No. 106].
57. Yager JD and Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3),270-282.